Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BG-75202 in Advanced Solid Tumors
NCT07222267Phase 1Recruiting
- Sponsor
- BeOne Medicines
- Start
- Dec 2025
- Primary completion
- Sep 2029
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 1, open-label trial of BG-75202 in breast cancer and solid tumor (5 arms), sponsored by BeOne Medicines. Primary endpoints: Number of Participants with Adverse Events up to 2 years, Recommended Dose for Expansion at 1 year and 1 more. Started Dec 2025; status: recruiting.
02
Drugs
BG-75202
03
Conditions
breast cancersolid tumor
Beyond the preview
Go deeper on NCT07222267.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07222267.